{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:14:23Z","timestamp":1792088063733,"version":"4.4.0"},"reference-count":47,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Access to crizanlizumab, a disease\u2010modifying therapy for sickle cell disease (SCD), was provided through a managed access program (MAP, NCT03720626). The present analysis evaluated the impact of 12\u2009months of crizanlizumab treatment on vaso\u2010occlusive crises (VOCs), and on the use of opioids for VOC\u2010related pain relief, in patients with SCD from the MAP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From June 2018 to January 2023, 112 patients with a history of recurrent VOCs completed 12\u2009months of crizanlizumab (5\u2009mg\/kg) treatment and were monitored for adverse events (AEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Crizanlizumab led to reductions of 18.0% and 36.2% in the proportions of patients having \u2265\u20091 home\u2010 and \u2265\u20091 healthcare\u2010managed VOCs. Median absolute changes (interquartile range) from baseline in the rates of home\u2010 and healthcare\u2010managed VOCs were \u22123.0 (\u22126.0, \u22121.0) and \u22122.0 (\u22124.0, 0), respectively. Data stratified by genotype and prior hydroxyurea use showed similar reductions in VOC rates. A 35.5% reduction in the proportion of patients requiring opioids was noted. AEs were consistent with earlier reports, and no new safety concerns were identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Crizanlizumab demonstrated potential benefits in attenuating VOC episodes, irrespective of SCD genotype and prior hydroxyurea use, and in lowering opioid usage. The safety of crizanlizumab was consistent with earlier reports.<\/jats:p><jats:p>\n<jats:bold>Trial Registration:<\/jats:bold> The MAP has been registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> with the ID, NCT03720626<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14323","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T06:00:16Z","timestamp":1730268016000},"page":"293-302","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real\u2010World Evidence of Crizanlizumab Showing Reductions in Vaso\u2010Occlusive Crises and Opioid Usage in Sickle Cell Disease"],"prefix":"10.1111","volume":"114","author":[{"given":"Laurie","family":"DeBonnett","sequence":"first","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Joshi","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd.  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cristina","family":"Silva\u2010Pinto","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Hematology and Oncology, Ribeir\u00e3o Preto School of Medicine University of S\u00e3o Paulo  Sao Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Colombatti","sequence":"additional","affiliation":[{"name":"Azienda Ospedale\u2010Universit\u00e0 di Padova  Padova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Pasanisi","sequence":"additional","affiliation":[{"name":"Centro Microcitemia\u2010UOC Ematologia Con Trapianto  Brindisi Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Arcioni","sequence":"additional","affiliation":[{"name":"SC Pediatric Onco\u2010Hematology With Bone Marrow Transplantation Azienda Ospedaliera di Perugia  Perugia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo D.","family":"Can\u00e7ado","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology Hospital Samaritano  Sao Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Sarp","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra","family":"Sarkar","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd.  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3473-9139","authenticated-orcid":false,"given":"Wesam","family":"Soliman","sequence":"additional","affiliation":[{"name":"Novartis Saudi Ltd.  Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00118-7"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30193-9"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214355"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510865"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2201763"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.10"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117175"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61029-X"},{"key":"e_1_2_10_10_1","volume-title":"Principles of Critical Care","author":"Hall J. B.","year":"2015"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2013.09.001"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2021.102612"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001851"},{"key":"e_1_2_10_14_1","unstructured":"National Heart Lung and Blood Institute \u201cEvidence\u2010Based Management of Sickle Cell Disease: Expert Panel Report 2014 \u201daccessed 30 October 2023 https:\/\/www.nhlbi.nih.gov\/files\/docs\/guidelines\/sc_mngt.pdf."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004394C"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-745711"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01237-z"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct0708272"},{"key":"e_1_2_10_19_1","unstructured":"\u201cSiklos. Hydroxycarbamide. Summary of Product Characteristics \u201daccessed June 30 2023 Siklos INN\u2010 Hydroxycarbamide (europa.eu)."},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009049"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.765958"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715971"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0713"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-285718"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23147"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611770"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25308"},{"key":"e_1_2_10_28_1","unstructured":"\u201cAdakveo (Crizanlizumab) Prescribing Information \u201daccessed 30 September 2023 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761128s001lbl.pdf."},{"key":"e_1_2_10_29_1","unstructured":"\u201cMAP to Provide Access to Crizanlizumab for Sickle Cell Disease Patients. NCT03720626. Study Details MAP to Provide Access to Crizanlizumab for Sickle Cell Disease Patients \u201daccessed 17 March 2023 ClinicalTrials.gov."},{"key":"e_1_2_10_30_1","unstructured":"\u201cAdakveo (Crizanlizumab) Summary of Product Characteristics \u201daccessed 20 November 2022 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/adakveo\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008209"},{"key":"e_1_2_10_32_1","unstructured":"\u201cEuropean Commission (EC) Adopts Decision Endorsing CHMP Recommendation to Revoke the Conditional Marketing Authorization for Adakveo\u00ae (Crizanlizumab) \u201daccessed September 4 2023 European Commission (EC) adopts decision endorsing CHMP recommendation to revoke the conditional marketing authorization for Adakveo\u00ae (crizanlizumab) | Novartis."},{"key":"e_1_2_10_33_1","unstructured":"EMA \u201cAdakveo Overview \u201daccessed July 1 2023 Adakveo | European Medicines Agency (europa.eu)."},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13362"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000002155"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb07980.x"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.4103\/0971-6866.73410"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-2-200801150-00004"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26576"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26063"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02412-5"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/014107680209500909"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000143"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e318188b2ab"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.2190\/7XMD-L45D-47DH-7MEC"},{"key":"e_1_2_10_46_1","unstructured":"B. D.Benites \u201cCrizanlizumab and Sickle Cell Anemia: Discussion of Complex Cases \u201d2022presented at HEMO Congress."},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.0475"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1095860"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T13:52:51Z","timestamp":1737467571000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/ejh.14323"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14323","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"2024-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}